New drugs: fenoldopam mesylate, glycoprotein IIb/IIIa antagonists, and K+ATP-channel agonists.
Vijayakumar
Elamana
E
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects; D004594:Electrophysiology; D018818:Fenoldopam / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D019194:Ischemic Preconditioning; D007668:Kidney / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015221:Potassium Channels / Q000819:agonists* / Q000502:physiology*; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D015221:Potassium Channels; D013453:Sulfonylurea Compounds; D014665:Vasodilator Agents; D018818:Fenoldopam